Page last updated: 2024-09-03

gefitinib and Carcinoma, Anaplastic

gefitinib has been researched along with Carcinoma, Anaplastic in 41 studies

Research

Studies (41)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	24 (58.54)	29.6817
2010's	17 (41.46)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Liu, F; Liu, Y; Luo, H; Wu, Y; Zhao, Y	1
Lu, H; Xie, Z; Xu, Y	1
Koch, A; Mischak, M; Niehus, SE; Tran, DDH	1
Kenzaka, T; Miyoshi, K; Nakaji, H	1
Deng, XB; Jin, ZR; Li, XQ; Liu, QZ; Liu, Y; Ma, L; Miao, XB; Sun, DX; Testa, JR; Wu, Y; Xiao, GH; Yao, KT; Zhang, G	1
Chan, KS; Lim, KH; Lim, WT; Lynette, O; Montoya, J; Ng, QS; Sakktee Krisna, S; Takano, A; Tan, DS; Tan, EH	1
Aasrum, M; Brusevold, IJ; Christoffersen, T; Sandnes, D; Tveteraas, IH; Ødegård, J	1
Chang, WC; Chu, YY; Hour, TC; Li, CF; Wang, JM; Wang, WJ; Wang, YH; Yen, CJ	1
Coombes, RC; Francis, RE; Guest, SK; Krol, J; Kwok, JM; Lam, EW; McGovern, UB; Myatt, SS; Peck, B; Polychronis, A; Wang, J	1
Li, L; Li, XQ; Liu, H; Liu, XJ; Zhen, YS	1
Choi, YJ; Kim, CH; Lee, JC; Lee, JK; Lee, SS; Na, II; Rho, JK; Ryoo, BY; Yang, SH; Yoo, YD	1
Iwakawa, J; Kawamata, Y; Kumamoto, T; Suetsugu, T; Tanoue, A	1
Azzariti, A; Colucci, G; Fratto, ME; Galluzzo, S; Maiello, E; Santini, D; Silvestris, N; Tommasi, S; Tonini, G; Vincenzi, B; Zoccoli, A	1
Fujita, Y; Hiroshima, K; Niijima, M; Nishio, K; Saitoh, M; Takiguchi, Y; Tatsumi, K	1
Gooding, WE; Grandis, JR; Gubish, CT; Siegfried, JM; Stabile, LP; Xu, H	1
He, BF; Huang, BY; Luo, RC; Sun, AM; Wang, WJ; Zheng, XK	1
Hashimoto, K; Komune, S; Nakano, T; Nakashima, T; Oda, Y; Oyama, M; Shiratsuchi, H; Tamiya, S; Yamamoto, H	1
Higashiyama, M; Kimura, T; Kiura, K; Kondoh, K; Kudoh, S; Minami, Y; Mitsudomi, T; Noguchi, M; Nokihara, H; Oda, M; Ohe, Y; Saito, H; Tachibana, K; Takeuchi, S; Tanaka, H; Uramoto, H; Yamada, T; Yano, S; Yasumoto, K; Yatabe, Y; Yokota, J; Yoshida, J	1
Fujii, M; Hasegawa, Y; Ijichi, K; Kondo, E; Maseki, S; Murakami, S; Nakanishi, H; Ogawa, T; Tanaka, H	1
Chang, YC; Chang, YL; Hu, FC; Lee, YC; Shih, JY; Wu, JY; Wu, SG; Yang, PC; Yu, CJ	1
Ai, Z; Teng, Y; Tong, J; Wang, J; Xu, Y	1
Bekele, BN; Doan, D; El-Naggar, AK; Holsinger, FC; Jasser, SA; Kim, S; Mandal, M; McMurphy, AB; Myers, JN; Schiff, BA; Sherman, SI; Yeung, SC; Yigitbasi, OG; Younes, MN; Zhou, G	1
Hirakawa, K; Ishikawa, T; Nobuhara, Y; Ogisawa, K; Onoda, N; Takashima, T; Yamasaki, M; Yamashita, Y	1
Carpentier, AF; Delattre, JY; Hoang-Xuan, K; Marie, Y; Omuro, AM; Sanson, M; Thillet, J	1
Arciero, CA; Chen, X; Darcy, KM; Decesare, SL; Godwin, AK; Lee, RB; Lewandowski, G; Schilder, RJ; Sill, MW; Wu, H	1
Ajiki, T; Digiovanni, J; Kawamoto, T; Kiguchi, K; Ruffino, L	1
Amadori, D; Brigliadori, G; Fabbri, F; Granato, AM; Rosetti, M; Tesei, A; Ulivi, P; Vannini, I; Zoli, W	1
Bidart, JM; Duvillard, P; Lacroix, L; Motté, N; Pautier, P; Saulnier, P; Soria, JC	1
Guo, M; Herman, JG; Liu, S; Lu, F; Zhuang, H	1
Albanell, J; Baselga, J; Doi, T; Koizumi, W; Ohtsu, A; Ramon Cajal, S; Ramon y Cajal, S; Rojo, F; Shirao, K; Tabernero, J; Takiuchi, H; Van Cutsem, E	1
Asada, K; Chida, K; Hasegawa, H; Naito, T; Suda, T	1
Burchert, A; Dietrich, C; Gläser, S; Hoffmann, S; Lingelbach, S; Müller, H; Rothmund, M; Wunderlich, A; Zielke, A	1
Barrow, D; Burmi, RS; Gee, JM; Hutcheson, IR; Jones, HE; Knowlden, JM; McClelland, RA; Nicholson, RI	1
Aakre, ME; Arteaga, CL; Bonine-Summers, AR; Brown, KA; Cheng, N; Moses, HL; Pietenpol, JA	1
Koldenhof, JJ; Sigurdsson, V; Tjin-A-ton, ML; van Montfrans, C; Voest, EE; Witteveen, PO	1
Aguilera, J; Chang, C; Chen, JS; Lopez, JP; Ongkeko, WM; Pardo, FS; Wang-Rodriguez, J	1
Fujisaki, R; Gu, Z; Horii, A; Inomata, K; Inoue, A; Kondo, T; Nukiwa, T; Sakurada, A; Sato, M; Yamanaka, S	1
Aguilera, J; Chang, CY; Lopez, JP; Ongkeko, WM; Pardo, FS; Sneh, G; Wang-Rodriguez, J; Yu, MA	1
Sherman, SI	1
Arteaga, CL; Carter, MB; Chinratanalab, W	1
Stratford, IJ; Telfer, BA; Wedge, SR; Williams, KJ	1

Reviews

4 review(s) available for gefitinib and Carcinoma, Anaplastic

Article	Year
Targeting EGFR in bilio-pancreatic and liver carcinoma. Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib	2011
Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-related cancer, 2006, Volume: 13 Suppl 1 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin Receptor Substrate Proteins; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoproteins; Quinazolines; Signal Transduction	2006
Early clinical studies of novel therapies for thyroid cancers. Endocrinology and metabolism clinics of North America, 2008, Volume: 37, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms	2008
Inhibitors of HER2/neu (erbB-2) signal transduction. Seminars in oncology, 2001, Volume: 28, Issue:6 Suppl 18 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Proto-Oncogene Mas; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2001

Trials

3 trial(s) available for gefitinib and Carcinoma, Anaplastic

Article	Year
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Catalytic Domain; Cloning, Molecular; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunohistochemistry; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Polymerase Chain Reaction; Protein Structure, Tertiary; Quinazolines; Recurrence; Time Factors; Treatment Outcome	2005
Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations. International journal of cancer, 2006, Feb-15, Volume: 118, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Ovarian Neoplasms; Paclitaxel; Quinazolines; Treatment Outcome	2006
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Sep-10, Volume: 24, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Area Under Curve; Biomarkers, Tumor; Carcinoma; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Stomach Neoplasms	2006

Other Studies

34 other study(ies) available for gefitinib and Carcinoma, Anaplastic

Article	Year
Construction of EGFR peptide gefitinib/quantum dots long circulating polymeric liposomes for treatment and detection of nasopharyngeal carcinoma. Biochemical and biophysical research communications, 2017, 08-19, Volume: 490, Issue:2 Topics: Antineoplastic Agents; Carcinoma; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gefitinib; Humans; Liposomes; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Peptides; Polymers; Quantum Dots; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured	2017
Detection of epidermal growth factor receptor mutation in the peripheral blood of patients with esophageal carcinoma to guide epidermal growth factor receptor-tyrosine kinase inhibitor treatment. Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:1 Topics: Adult; Aged; Alleles; Antineoplastic Agents; Carcinoma; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome	2018
Colony-stimulating factor-1 receptor provides a growth advantage in epithelial cancer cell line A431 in the presence of epidermal growth factor receptor inhibitor gefitinib. Cellular signalling, 2018, Volume: 51 Topics: Anilides; Animals; Antineoplastic Agents; Carcinoma; Cell Proliferation; Databases, Genetic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HeLa Cells; Hep G2 Cells; Humans; Macrophage Colony-Stimulating Factor; Macrophages; Mice; Mice, Inbred C57BL; Phosphorylation; Pyridines; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Signal Transduction; Skin Neoplasms	2018
Iatrogenic pneumopericardium in the setting of carcinomatous pericarditis. BMJ case reports, 2018, Oct-12, Volume: 2018 Topics: Adenocarcinoma of Lung; Aged; Carcinoma; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Pericarditis; Pneumopericardium; Protein Kinase Inhibitors; Punctures; Radiography; Ventilators, Negative-Pressure	2018
Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma. The FEBS journal, 2013, Volume: 280, Issue:9 Topics: Animals; Antineoplastic Agents; beta Catenin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cisplatin; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanog Homeobox Protein; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Neoplastic Stem Cells; Proto-Oncogene Proteins c-akt; Quinazolines; Side-Population Cells; Signal Transduction; Spheroids, Cellular; Xenograft Model Antitumor Assays	2013
Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, May-10, Volume: 31, Issue:14 Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Biopsy; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Immunohistochemistry; Leucine; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Unknown Primary; Point Mutation; Quinazolines; Tomography, X-Ray Computed	2013
Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:2 Topics: Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; DNA; ErbB Receptors; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Lysophospholipids; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transcriptional Activation	2016
Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Jan-15, Volume: 23, Issue:2 Topics: Aminosalicylic Acids; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; CCAAT-Enhancer-Binding Protein-delta; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Protein 2; Paclitaxel; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Urinary Bladder Neoplasms; Urothelium	2017
Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Molecular cancer therapeutics, 2009, Volume: 8, Issue:3 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Case-Control Studies; Cell Death; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Forkhead Box Protein O3; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Quinazolines; RNA, Small Interfering; Tumor Cells, Cultured	2009
Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells. Anti-cancer drugs, 2009, Volume: 20, Issue:1 Topics: Aminoglycosides; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enediynes; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2009
The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Molecular cancer research : MCR, 2009, Volume: 7, Issue:10 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines	2009
[A case of meningeal carcinomatosis of lung adenocarcinoma well controlled by re-treatment with gefitinib]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:13 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Meningeal Neoplasms; Mutation; Paclitaxel; Quinazolines	2009
An early event of EGFR mutation in pleomorphic carcinoma of the lung. International journal of clinical oncology, 2011, Volume: 16, Issue:6 Topics: Antineoplastic Agents; Carcinoma; Cell Transformation, Neoplastic; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines	2011
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-01, Volume: 17, Issue:13 Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Hepatocyte Growth Factor; Humans; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasms, Squamous Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transforming Growth Factor alpha; Wound Healing; Xenograft Model Antitumor Assays	2011
[Gefitinib enhances the radiosensitivity of nasopharyngeal carcinoma cell line CNE2 in vitro]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:6 Topics: Apoptosis; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Gefitinib; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Quinazolines; Radiation Tolerance	2011
Tumor-to-tumor metastasis: lung adenocarcinoma metastasizing to a follicular variant of papillary thyroid carcinoma. Pathology international, 2011, Volume: 61, Issue:7 Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Combined Modality Therapy; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome	2011
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Hepatocyte Growth Factor; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines	2011
Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway. British journal of cancer, 2012, Mar-13, Volume: 106, Issue:6 Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Phenotype; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Snail Family Transcription Factors; Transcription Factors	2012
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. The European respiratory journal, 2013, Volume: 41, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiography, Thoracic; Time Factors; Treatment Outcome	2013
Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model. The journal of obstetrics and gynaecology research, 2012, Volume: 38, Issue:12 Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endometrial Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Phosphorylation; Quinazolines; Receptors, Progesterone; Signal Transduction; Xenograft Model Antitumor Assays	2012
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Quinazolines; Thyroid Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured	2004
Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. British journal of cancer, 2005, Mar-28, Volume: 92, Issue:6 Topics: Animals; Carcinoma; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Transplantation; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Thyroid Neoplasms; Transplantation, Heterologous	2005
EGFR tyrosine kinase domain mutations in human gliomas. Neurology, 2005, Apr-26, Volume: 64, Issue:8 Topics: Astrocytoma; Brain Neoplasms; Carcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Testing; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Oligodendroglioma; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines	2005
Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15 Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Blotting, Western; Body Weight; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Enzyme Inhibitors; ErbB Receptors; Gallbladder; Gallbladder Neoplasms; Gefitinib; Humans; In Situ Nick-End Labeling; MAP Kinase Signaling System; Mice; Mice, Transgenic; Microscopy, Fluorescence; Neoplasms, Experimental; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tolonium Chloride	2005
Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines. Cancer biology & therapy, 2005, Volume: 4, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Quinazolines	2005
Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. Cancer biology & therapy, 2006, Volume: 5, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Mutation, Missense; Protein Structure, Tertiary; Quinazolines	2006
Lymphangitis carcinomatosis as a potential predictor for a response to gefitinib. Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:7 Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Female; Forecasting; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Male; Quinazolines; Treatment Outcome	2006
Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbeck's archives of surgery, 2006, Volume: 391, Issue:6 Topics: Carcinoma; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Vascular Endothelial Growth Factor A	2006
Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer biology & therapy, 2007, Volume: 6, Issue:4 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Mammary Glands, Human; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases	2007
[Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors]. Nederlands tijdschrift voor geneeskunde, 2007, Apr-28, Volume: 151, Issue:17 Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma; Cetuximab; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines	2007
Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Archives of otolaryngology--head & neck surgery, 2007, Volume: 133, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Blotting, Western; Carcinoma; Cell Line, Tumor; Cell Proliferation; Culture Media; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Neoplasm Proteins; Quinazolines; RNA, Neoplasm; Thyroid Neoplasms	2007
siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma. Pathobiology : journal of immunopathology, molecular and cellular biology, 2008, Volume: 75, Issue:1 Topics: Antineoplastic Agents; Blotting, Western; Carcinoma; DNA Mutational Analysis; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Gene Targeting; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering	2008
Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines. The Laryngoscope, 2008, Volume: 118, Issue:8 Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Phosphorylation; Quinazolines; Thyroid Neoplasms	2008
ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. British journal of cancer, 2002, Apr-08, Volume: 86, Issue:7 Topics: Animals; Carcinoma; Cell Division; Chemotherapy, Adjuvant; Colorectal Neoplasms; Enzyme Inhibitors; Gefitinib; Humans; Mice; Quinazolines; Radiation-Sensitizing Agents; Transplantation, Heterologous	2002